Pan-tumor MRD Study

You may be eligible if

• Eligibility Criteria:
• 1. Age 18 years or older.
• 2. Confirmed histological or cytological diagnosis of a malignant solid tumor that is either specified in one of the pre-defined tumor cohorts or meets the enrollment criteria for the Mix of Solid Tumors (MOST) cohort (Table 1).
• 3. Eligible for curative intent therapy, with surgical resection of cancer planned.
• a. If surgical resection has occurred, enrollment should occur within 3 months of surgical resection and before initiation of adjuvant therapy.
• 4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2.
• 5. No systemic therapy for current cancer diagnosis administered before enrollment.
• 6. Willing and able to comply with required study procedures, including blood sample collection and primary tumor tissue submission from diagnostic biopsy or surgical excision.
• 7. Has completed all therapy (including endocrine therapy) 3 or more years ago for any previous invasive solid organ malignancy (with exception of nonmelanoma skin cancers) or hematologic malignancy. Individuals with a prior history of noninvasive (in situ) carcinomas may participate if they have received definitive treatment (no washout period required).
• 8. No concurrent diagnosis of another invasive cancer, except for nonmelanoma skin cancers.
• 9. No prior allogeneic hematopoietic stem cell transplant.
• 10. Able and willing to provide informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for the release of personal health information.
• Cohort Specific Criteria
• 11. Muscle-invasive urothelial carcinoma of the bladder and Melanoma Cohorts: Stage II or operable III cancer:
• 12. Esophageal, Gastric/GEJ, and NSCLC Cohorts: Stage I, II, or operable III cancer.
• 13. Pancreatic Cohort: Stage I, II or operable III cancer, exocrine only disease.
• 14. MOST cohort: Stage II or operable stage III solid tumor diagnosis that meets eligibility criteria and is not included in the other cohorts.
• The following tumor types are excluded:
• 1. Central nervous system (CNS) malignancies
• 2. Colorectal cancer
• 3. Breast cancer
• 4. Squamous cell skin cancer
• 5. Basal cell carcinoma
• 6. Gastrointestinal stromal tumors (GIST)
• 7. Thyroid cancer
• 8. Uveal melanoma
• 9. Low or intermediate grade neuroendocrine tumors
• ■ Eligible tumor types: High-grade neuroendocrine tumors, including neuroendocrine carcinomas, Merkel cell carcinomas, and small cell lung cancer are permissible
• 10. Hematologic cancers including multiple myeloma or other plasma cell dyscrasias, Hodgkin\'s lymphoma, non-Hodgkin\'s lymphoma, acute or chronic leukemias including chronic lymphocytic leukemia / small lymphocytic leukemia